



(/content/hn-library-ca/en_us.html.html)



Language ▼

HealthNet.com (<https://healthnet.com>)

News

20-648 New Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table - 3rd Quarter 2020

Date: 09/01/20

This information applies to Participating Physician Groups (PPGs).

For Medi-Cal, this information applies to Kern, Los Angeles, Riverside, Sacramento, San Bernardino, San Diego, San Joaquin, Stanislaus, and Tulare counties.

The updates are effective for dates of service on and after November 3, 2020

On July 14, 2020, the Health Net Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective November 3, 2020, are listed below. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net and CalViva Health Provider Participation Agreement (PPA).

The update includes:

- 12 new injectable medications and DOFR categories.
- 18 updates and changes to injectable medication procedure codes.
- 1 changes to existing DOFR categories.

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website (<http://provider.healthnet.com>).

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com (mailto:provider_services@healthnet.com) within 60 days.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
C9059	Anjeso™	Meloxicam injection, for intravenous use	Therapeutic injection	
J3490	Akovaz™	Ephedrine sulfate injection, USP for intravenous use	Therapeutic injection	
Q5121	Avsola™	Injection, infliximab-axxq, biosimilar, 10mg	Therapeutic injection	
A9590	Azedra®	lobenguane I 131 injection, for intravenous use	Therapeutic injection	Chemotherapy*
J3490	Defitelio®	Defibrotide sodium injection, for intravenous use	Therapeutic injection	
J7204	Esperoct®	Antihemophilic factor (recombinant), glycopegylated-exei is a coagulation Factor VIII concentrate indicated for use in adults and children with hemophilia A	Therapeutic injection	Blood/blood products for hemophilia

A9513	Lutathera®	Lutetium Lu 177 dotatate injection, for intravenous use	Therapeutic injection	Chemotherapy*
J1201	Quzyttir™	Cetirizine hydrochloride injection, for intravenous use	Therapeutic injection	
C9399	Sarclisa®	Isatuximab-irfc injection, for intravenous use	Therapeutic injection	Chemotherapy*
J9999	Trodelvy™	Sacituzumab govitecan-hziy for injection, for intravenous use	Therapeutic injection	Chemotherapy*
J7333	Visco-3™	Hyaluronan or derivative for intra-articular injection, per dose	Therapeutic injection	
J0691	Xenleta™	Lefamulin injection, for intravenous use	Therapeutic injection	Home health/infusion**

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J1815	Insulin	Injection, insulin, per 5 units	Clarification

J0791	Adakveo®	Crizanlizumab-tmca IV Solution	Updated from J3590,C9053
J9245	Alkeran®	Melphalan hydrochloride, not otherwise specified, 50 mg	Updated description
J7169	Andexxa®	Injection, coagulation factor Xa (recombinant), inactivated	Updated from C9041
J9246	Evomela®	Melphalan 1 mg	Updated from J9245
J9358	Enhertu®	Fam-trastuzumab deruxtecan-nxki for IV Solution	Updated from J9999
J0223	Gilvaari™	Givosiran injection, for Subcutaneous use	Updated from J3490, C9056
J9198	Infugem®	Gemcitabine hydrochloride, Injection	Updated from J1999
J9177	Padcev™	Enfortumab vedotin-ejfv for IV Solution	Updated from J9999
J0742	Recarbrio™	Imipenem, cilastatin, and relebactam for injection, for intravenous use	Updated from J3490
J0896	Reblozyl®	Luspatercept-aamt for Subcutaneous inj	Updated from J3590
Q5119	Ruxience™	Rituximab-pvvr (Rituxan biosimilar)	Updated from J1999

C9122	Sinuva™	Mometasone furoate sinus implant, 10 micrograms	Updated from J7401
C9061	Tepezza™	Atezolizumab	Updated from J3590
J1429	Vyondys 53™	Golodirsen IV Solution	Updated from J3490
J1558	Xembify®	Immune Globulin Subcutaneous, human-klhw 20%	Updated from J3590
Q5120	Ziextenzo™	Pegfilgrastim-bmez injection, for Subcutaneous use	Updated from J3590
J3399	Zolgensma™	Onasemnogene abeparvovec-xioi	Updated from J3490

Category changes

The following medication has been approved by the Health Net P&T Committee to add the Secondary Category of Home Health Infusion.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0791	Adakveo®	Crizanlizumab-tmca IV Solution	Therapeutic injection	Home health/infusion**

HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS (<http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html>) website.

*If associated with an ICD-10 cancer diagnosis.

****When administered by a nurse in a home setting.**

Last Updated: 08/31/2020

[Terms & Conditions \(/terms-conditions.html\)](/terms-conditions.html)

[Nondiscrimination Notice \(/non-discrimination-notice.html\)](/non-discrimination-notice.html)

[Privacy Policy \(/privacy-policy.html\)](/privacy-policy.html)

[Notice of Privacy Practices \(/privacy-practices.html\)](/privacy-practices.html)

You will need Adobe Reader to open PDFs on this site.

Download the free version of Adobe Reader. (<https://get.adobe.com/reader/>)



(<https://get.adobe.com/reader/>)

© Copyright 2020 Health Net, Inc.